GAITHERSBURG, Md., Jan. 8 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced the departure of senior vice president and
chief financial officer, Gregory S. Patrick.
Commenting on Mr. Patrick's departure, David M. Mott, MedImmune's chief
executive officer said, "We would like to thank Greg for his many
contributions to the growth of MedImmune over the past three years, and wish
him much additional success in his future endeavors."
As MedImmune searches for a replacement for Mr. Patrick, the company's
current vice president and controller, Lota S. Zoth, will assume the role of
acting chief financial officer, while maintaining her duties of managing the
day-to-day activities of the finance and accounting departments.
About MedImmune, Inc.
MedImmune is a leading biotechnology company focused on researching,
developing and commercializing products to prevent or treat infectious
disease, autoimmune disease and cancer. MedImmune actively markets four
products, Synagis(R) (palivizumab), FluMist(TM) (Influenza Virus Vaccine Live,
Intranasal), Ethyol(R) (amifostine) and CytoGam(R) (cytomegalovirus immune
globulin intravenous (human)), and has additional products in clinical
testing. MedImmune employs approximately 1,700 people, is headquartered in
Gaithersburg, Maryland, and has additional operations in Frederick, Maryland,
as well as Pennsylvania, California, the United Kingdom and the Netherlands.
For more information on the company and its products, visit MedImmune's
website at www.medimmune.com.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in MedImmune's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
/CONTACT: Media and Investors: Lori Weiman, +1-650-919-3753, or
Investors: Will Roberts, +1-301-527-4358, or John Filler, +1-240-632-4086, all
of MedImmune, Inc./
/Web site: http://www.medimmune.com/
CO: MedImmune, Inc.
IN: MTC BIO HEA
-- DCTH037 --
4424 01/08/2004 16:05 EST http://www.prnewswire.com